Sarepta Therapeutics ( NASDAQ: SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Sarepta said it was halting shipments of its Duchenne gene therapy for patients who can no longer walk, following the death ...

Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read ...

Sarepta Therapeutics said it has temporarily suspended shipments of Elevidys® (delandistrogene moxeparvovec-rokl) for ...

Sarepta Therapeutics Inc. said a second patient has died of acute liver failure after being treated with its gene therapy for ...

The estimated cost that Belfast Trust has produced seems high and does not align with any other figures we have seen from ...

After the completion of the 54th Italian-American Charity Golf Association Tournament on Saturday evening, it was time for ...

Retail investor chatter around Sarepta Therapeutics surged on Sunday after the company announced it had suspended shipments ...

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Therapeutics provided a safety update regarding Elevidys, an FDA approved gene therapy for patients with Duchenne muscular ...